Keros Therapeutics Inc. (KROS)
Keros Therapeutics Statistics
Share Statistics
Keros Therapeutics has 40.51M shares outstanding. The number of shares has increased by 12.57% in one year.
| Shares Outstanding | 40.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 7.96% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.86M |
| Failed to Deliver (FTD) Shares | 129.80K |
| FTD / Avg. Volume | 9.03% |
Short Selling Information
The latest short interest is 3.03M, so 7.47% of the outstanding shares have been sold short.
| Short Interest | 3.03M |
| Short % of Shares Out | 7.47% |
| Short % of Float | 9.77% |
| Short Ratio (days to cover) | 2.31 |
Valuation Ratios
The PE ratio is -7.65 and the forward PE ratio is -11.38.
| PE Ratio | -7.65 |
| Forward PE | -11.38 |
| PS Ratio | 7753.76 |
| Forward PS | 31.1 |
| PB Ratio | 3.52 |
| P/FCF Ratio | -9.22 |
| PEG Ratio | n/a |
Enterprise Valuation
Keros Therapeutics Inc. has an Enterprise Value (EV) of 854.11M.
| EV / Earnings | -5.58 |
| EV / Sales | 5656.39 |
| EV / EBITDA | -5.61 |
| EV / EBIT | -5.03 |
| EV / FCF | -6.73 |
Financial Position
The company has a current ratio of 14.25, with a Debt / Equity ratio of 0.04.
| Current Ratio | 14.25 |
| Quick Ratio | 14.25 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 4.17 |
| Cash Flow / Debt | -8.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -49.02%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.41% |
| Return on Capital (ROIC) | -49.02% |
| Revenue Per Employee | 943.75 |
| Profits Per Employee | -956.20K |
| Employee Count | 160 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -80.33% in the last 52 weeks. The beta is 1.24, so Keros Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.24 |
| 52-Week Price Change | -80.33% |
| 50-Day Moving Average | 34.05 |
| 200-Day Moving Average | 48.17 |
| Relative Strength Index (RSI) | 24.27 |
| Average Volume (20 Days) | 1.44M |
Income Statement
In the last 12 months, Keros Therapeutics had revenue of 151.00K and earned -152.99M in profits. Earnings per share was -5.2.
| Revenue | 151.00K |
| Gross Profit | -664.00K |
| Operating Income | -169.94M |
| Net Income | -152.99M |
| EBITDA | -152.18M |
| EBIT | -169.94M |
| Earnings Per Share (EPS) | -5.2 |
Balance Sheet
The company has 331.15M in cash and 14.44M in debt, giving a net cash position of 316.70M.
| Cash & Cash Equivalents | 331.15M |
| Total Debt | 14.44M |
| Net Cash | 316.70M |
| Retained Earnings | -381.43M |
| Total Assets | 579.27M |
| Working Capital | 523.04M |
Cash Flow
In the last 12 months, operating cash flow was -124.51M and capital expenditures -2.46M, giving a free cash flow of -126.97M.
| Operating Cash Flow | -124.51M |
| Capital Expenditures | -2.46M |
| Free Cash Flow | -126.97M |
| FCF Per Share | -4.31 |
Margins
Gross margin is -439.74%, with operating and profit margins of -112.54K% and -101.32K%.
| Gross Margin | -439.74% |
| Operating Margin | -112.54K% |
| Pretax Margin | -101.32K% |
| Profit Margin | -101.32K% |
| EBITDA Margin | -100.78K% |
| EBIT Margin | -112.54K% |
| FCF Margin | -84.09K% |
Dividends & Yields
KROS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -45.3% |
| FCF Yield | -27.3% |
Analyst Forecast
The average price target for KROS is $41, which is 257.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $41 |
| Price Target Difference | 257.1% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 4.89 |
| Piotroski F-Score | 5 |